Simulations Plus Faces Scrutiny After Guidance Cut, Impairment Charge, and Auditor Dismissal
Event summary
- Simulations Plus cut its fiscal 2025 revenue guidance by ~$14M on June 11, 2025, citing market uncertainties in pharmaceutical and biotech sectors.
- The company reported a $67.3M net loss in Q3 2025, including a $77.2M non-cash impairment charge.
- Simulations Plus dismissed auditor Grant Thornton LLP on July 15, 2025, over unresolved issues in segment reporting and internal controls.
- Grant Thornton disputed the dismissal, stating unresolved matters in its SEC filing.
- The stock dropped 24% in June 2025 and another 26% in July 2025 following these disclosures.
The big picture
Simulations Plus's recent financial disclosures and auditor dismissal highlight growing governance and market risks in the biotech software sector. The company's ability to navigate these challenges will be critical as it seeks to stabilize its financial performance and restore investor confidence. The broader industry is also grappling with budget constraints and project delays, which could further impact companies reliant on pharmaceutical and biotech clients.
What we're watching
- Governance Dynamics
- How Simulations Plus will address the unresolved accounting and internal control issues identified by Grant Thornton.
- Market Volatility
- Whether the company can stabilize its revenue streams amid budget reductions and project delays in the pharmaceutical sector.
- Investor Confidence
- The pace at which Simulations Plus can regain investor trust following the guidance cut and auditor dispute.
Related topics